Correction to: Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation.

Liang, Emily C; Chen, Connie; Lu, Rong; Mannis, Gabriel N; Muffly, Lori

Liang, Emily C; Chen, Connie; Lu, Rong; Mannis, Gabriel N; Muffly, Lori.

Afiliação

Liang EC; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Chen C; Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA.
Lu R; Department of Medicine, Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA, USA.
Mannis GN; Department of Medicine, Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA.
Muffly L; Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA. lmuffly@stanford.edu.

Bone Marrow Transplant ; 57(4): 694, 2022 Apr.

Article em En | MEDLINE | ID: mdl-35169285

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article